The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial

被引:8
|
作者
Heimburger, Sebastian M. N. [1 ,2 ,3 ]
Hoe, Bjorn [1 ,4 ]
Nielsen, Chris N. [1 ]
Bergmann, Natasha C. [1 ]
Hartmann, Bolette [3 ,5 ]
Holst, Jens J. [3 ,5 ]
Vilsboll, Tina [1 ,2 ,4 ]
Dejgaard, Thomas F. [1 ,2 ]
Christensen, Mikkel B. [1 ,4 ,6 ,7 ]
Knop, Filip K. [1 ,2 ,3 ,4 ]
机构
[1] Univ Copenhagen, Gentofte Hosp, Ctr Clin Metab Res, Hellerup, Denmark
[2] Steno Diabet Ctr Copenhagen, Gentofte, Denmark
[3] Univ Copenhagen, Fac Hlth & Med Sci, Novo Nordisk Fdn Ctr Basic Metab Res, Copenhagen, Denmark
[4] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark
[5] Univ Copenhagen, Fac Hlth & Med Sci, Dept Biomed Sci, Copenhagen, Denmark
[6] Univ Copenhagen, Bispebjerg Hosp, Dept Clin Pharmacol, Copenhagen, Denmark
[7] Univ Copenhagen, Bispebjerg Hosp, Copenhagen Ctr Translat Res, Copenhagen, Denmark
关键词
Adipose tissue; Continuous glucose monitoring; GIP; Glucose-dependent insulinotropic polypeptide; Glycaemic control; Glycaemic time in range; Hypoglycaemia; Hypoglycaemic events; Insulin resistance; Insulin sensitivity; RECEPTOR AGONIST; GLUCAGON; HYPOGLYCEMIA; RESPONSES;
D O I
10.1007/s00125-021-05547-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis Type 1 diabetes is characterised by reduced glucagon response to hypoglycaemia, increasing the risk of insulin treatment-associated hypoglycaemia known to hamper glycaemic control. We previously reported a glucagonotropic effect of exogenous glucose-dependent insulinotropic polypeptide (GIP) during insulin-induced hypoglycaemia in individuals with type 1 diabetes. Here we investigate the effect of a 6-day s.c. GIP infusion on time in glycaemic range as assessed by continuous glucose monitoring (CGM) in individuals with type 1 diabetes. Methods In a randomised, placebo-controlled, double-blind crossover study, time in glycaemic range (assessed by double-blinded CGM) was evaluated in 20 men with type 1 diabetes (18-75 years, stable insulin treatment >= 3 months, diabetes duration 2-15 years, fasting plasma C-peptide below 200 pmol/l, BMI 20-27 kg/m(2), HbA(1c) <69 mmol/mol [8.5%]) during two x 6 days of continuous s.c. GIP (6 pmol kg(-1) min(-1)) and placebo (saline [154 mmol/l NaCl]) infusion, respectively, with an interposed 7-day washout period. The primary outcome was glycaemic time below range, time in range and time above range. Results There were no significant differences in time below range (<3.9 mmol/l, p = 0.53) or above range (>10 mmol/l, p = 0.32) during night-time or daytime, in mean glucose, or in hypoglycaemic events as assessed by CGM. GIP altered neither self-reported hypoglycaemia nor safety measures. Compared with placebo, GIP significantly increased time in tight range (3.9-7.8 mmol/l) during daytime (06:00-23:59 hours) by [mean +/- SEM] 11.2 +/- 5.1% [95% CI 0.41, 21.9] (p = 0.02). Conclusions/interpretation Six-day s.c. GIP infusion in men with type 1 diabetes did not procure convincing effect on overall time in range, but increased time in tight glycaemic range during daytime by similar to 2 h per day.
引用
收藏
页码:2425 / 2431
页数:7
相关论文
共 50 条
  • [41] Effects of Melatonin on Glycemic Variability in Type 2 Diabetes Mellitus: Protocol for a Crossover, Double-Blind, Placebo-Controlled Trial
    Martorina, Wagner
    Tavares, Almir
    JMIR RESEARCH PROTOCOLS, 2023, 12
  • [42] Effect of Lingliptin and Voglibose on metabolic Profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial
    Parthan, Girish
    Bhansali, Shobhit
    Kurpad, Anura, V
    Walia, Rama
    Bhat, Kishor
    Bhansali, Anil
    BMC PHARMACOLOGY & TOXICOLOGY, 2018, 19
  • [43] Two weeks of acarbose treatment shows no effect on gut microbiome composition in patients with type 2 diabetes: a randomised, placebo-controlled, double-blind, crossover study
    Dalsgaard, Niels B.
    Gasbjerg, Laerke S.
    Hansen, Laura S.
    Nielsen, Dennis S.
    Rasmussen, Torben S.
    Knop, Filip K.
    ENDOCRINE CONNECTIONS, 2024, 13 (07)
  • [44] Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial
    Girish Parthan
    Shobhit Bhansali
    Anura V. Kurpad
    Rama Walia
    Kishor Bhat
    Anil Bhansali
    BMC Pharmacology and Toxicology, 19
  • [45] A Double-Blind, Placebo-Controlled, Crossover Trial Comparing the Effects of Amiloride and Hydrochlorothiazide on Glucose Tolerance in Patients With Essential Hypertension
    Stears, Anna J.
    Woods, Sarah H.
    Watts, Michaela M.
    Burton, Timothy J.
    Graggaber, Johann
    Mir, Fraz A.
    Brown, Morris J.
    HYPERTENSION, 2012, 59 (05) : 934 - 942
  • [46] Effect of cilostazol on arterial stiffness and vascular adhesion molecules in type 2 diabetic patients with metabolic syndrome: a randomised, double-blind, placebo-controlled, crossover trial
    Kim, Nam Hoon
    Kim, Hee Young
    An, Hyonggin
    Seo, Ji A.
    Kim, Nan Hee
    Choi, Kyung Mook
    Baik, Sei Hyun
    Choi, Dong Seop
    Kim, Sin Gon
    DIABETOLOGY & METABOLIC SYNDROME, 2013, 5
  • [47] Effect of cilostazol on arterial stiffness and vascular adhesion molecules in type 2 diabetic patients with metabolic syndrome: a randomised, double-blind, placebo-controlled, crossover trial
    Nam Hoon Kim
    Hee Young Kim
    Hyonggin An
    Ji A Seo
    Nan Hee Kim
    Kyung Mook Choi
    Sei Hyun Baik
    Dong Seop Choi
    Sin Gon Kim
    Diabetology & Metabolic Syndrome, 5
  • [48] Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial
    Johansen, Nicklas J.
    Dejgaard, Thomas F.
    Lund, Asger
    Schluntz, Camilla
    Frandsen, Christian S.
    Forman, Julie L.
    Albrechtsen, Nicolai J. Wewer
    Holst, Jens J.
    Pedersen-Bjergaard, Ulrik
    Madsbad, Sten
    Vilsboll, Tina
    Andersen, Henrik U.
    Knop, Filip K.
    LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (04): : 313 - 324
  • [49] The Effect of Glycopyrrolate on Nocturnal Sialorrhea in Patients Using Clozapine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial
    Man, Wai Hong
    Colen-de Koning, Jantine C. A.
    Schulte, Peter F. J.
    Cahn, Wiepke
    van Haelst, Ingrid M. M.
    Doodeman, Hieronymus J.
    Egberts, Toine C. G.
    Heerdink, Eibert R.
    Wilting, Ingeborg
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2017, 37 (02) : 155 - 161
  • [50] Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
    Roden, Michael
    Weng, Jianping
    Eilbracht, Jens
    Delafont, Bruno
    Kim, Gabriel
    Woerle, Hans J.
    Broedl, Uli C.
    LANCET DIABETES & ENDOCRINOLOGY, 2013, 1 (03): : 208 - 219